Top

Published in:

01-09-2008 | Original Research Article

Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy

Authors: Ulrika Kjellström, Monica Lövestam-Adrian, Sten Andréasson, Vesna Ponjavic

Published in: Documenta Ophthalmologica | Issue 2/2008

Abstract

Purpose In numerous studies vigabatrin medication has been associated with visual field constriction and alterations in the full-field electroretinogram (ff-ERG), but it is not clear whether these changes are reversible or not. The purpose of this study was to examine patients with visual field loss and reduced ff-ERG several years after discontinuing vigabatrin therapy, in order to investigate reversibility. Methods Eight patients with visual field constriction and reduced cone responses measured by 30 Hz flicker ERG were examined with Goldmann perimetry and ff-ERG 4–6 years after discontinuing medication. The results were compared with investigations conducted during medication, 4–6 years previously. Statistical analysis was also used to compare the ff-ERG results of the patients, during treatment and at follow-up, with a group of 70 healthy subjects. Results Visual field constriction remained 4–6 years after discontinuing vigabatrin therapy. The amplitude of the 30 Hz flicker response also remained reduced on follow-up both compared with the results during treatment and with the control group. Moreover, the amplitude of the isolated rod response and the combined rod–cone response were decreased in the patients compared with the control group, during vigabatrin treatment as well as on follow-up. On follow-up, oscillatory potentials (OPs) also were registered, showing reduced amplitudes in patients compared with controls. The within subject comparison showed no significant changes. Conclusion Vigabatrin attributed visual field constriction and reduced ff-ERG responses remain several years after discontinuing vigabatrin therapy, indicating drug-induced permanent retinal damage.

Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie M (2003) Vigabatrin, but not gabapentin or topiramat, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44:886–892PubMedCrossRef

Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180–181

Backström JT, Hinke RL, Flicker MR (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694–1695

Blackwell N, Hayllar J, Kelly G (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694

Harding GA (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694

Wilson EA, Brodie MJ (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1693

Wong ICK, Mawer GE, Sander JWAS (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694–1695

Kälviänen R, Nousianen I, Mänyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Reikkinen P (1999) Vigabatrin, a GABAergic antiepileptic drug, cause concentric visual field defects. Neurology 53:922–926

Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL (1999) Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiological findings. Neurology 53:2082–2087PubMed

10.

Nicolson A, Leach JP, Chadwick DW, Smith DF (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327–329PubMedCrossRef

11.

Ponjavic V, Andréasson S (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:63–72PubMedCrossRef

12.

Lawden MC, Eke T, Degg C, Harding GFA, Wild JM (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716–722PubMedCrossRef

13.

Daneshvar H, Racette MA, Coupland SG, Kertes PJ, Guberman A, Zackon D (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophtalmology 106:1792–1798CrossRef

14.

Nousiainen I, Mantyjarvi M, Kalviainen R (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:1916–1917PubMed

15.

Wild JM, Martinez C, Reinshagen G, Harding GF (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:1784–1794PubMedCrossRef

16.

Krauss GL, Johnson MA, Sheth S, Miller NR (2003) A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74:339–343PubMedCrossRef

17.

Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M (1998) Electrophysiological evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 116:817–819PubMed

18.

Graniewski-Wijnands HS, van der Torren K (2002) Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 104:189–194PubMedCrossRef

19.

Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B (2002) Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol 249:1066–1071PubMedCrossRef

20.

Newman WD, Tocher K, Acheson JF (2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16:567–571PubMedCrossRef

21.

Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, Van Veelen C (2003) Vigabatrin: longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 81:459–465PubMedCrossRef

22.

Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR (2000) Visual function loss from vigabatrin. Effect of stopping the drug Neurology 55:40–45

23.

Fledelius HC (2003) Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 81:41–45PubMedCrossRef

24.

Krakow K, Polizzi G, Riordan-Eva P, Holder G, Macleod W, Fish D (2000) Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 9:287–290PubMedCrossRef

25.

Versino M, Veggiotti P (1999) Reversibility of vigabatrin induced visual-field defect. Lancet 354:486PubMedCrossRef

26.

Hammond EJ, Rangel RJ, Wilder BJ (1988) Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 61:16–23

27.

Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, Perucca E (1989) Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 27:61–68

28.

Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P (1989) Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 27:69–72

29.

Mauguiere F, Chauvel P, Dewailly J, Dousse N (1997) No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy, result of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicentergroup. Epilepsia 38:301–308PubMedCrossRef

30.

Coupland SG, Zackon DH, Leonard BC, Ross TM (2001) Vigabatrin Effect on Inner Retinal Function. Ophthalmology 108:1493–1498PubMedCrossRef

31.

Westall CA, Nobile R, Morong S, Buncic RJ, Logan WJ, Panton CM (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107:299–309PubMedCrossRef

32.

Van der Torren K, Graniewski-Wijnands HS, Polak BCP (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104:181–188PubMedCrossRef

33.

Comaish IF, Gorman C, Brimlow GM, Barber C. Orr GM, Galloway NR (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104:195–2129PubMedCrossRef

34.

McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, Keating D, Sills GJ, Brodie MJ (2003) Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61:1690–1694PubMed

35.

Scaioli V, Franceschetti S, Binelli S, Casazza M, Villani F, Granata T, Balestrini MR, Curzi S, Agazzi P, Avanzini G (2005) Serial electrophysiological studies of the visual pathway in patients treated with vigabatrin. Int Congr Ser 1278:41–44CrossRef

36.

Besch D, Kurtenbach A, Appfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, Schiefer U (2002) Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104:151–170PubMedCrossRef

37.

Marmor MF, Holder GE, Seelinger MW, Yamamoto S. International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107–114

38.

Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminas inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695–705PubMedCrossRef

39.

Frisèn L, Malmgren K (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466–473PubMedCrossRef

40.

Buncic RJ, Westall CA, Panton CM, Munn RJ, MacKeen LD, Logan WJ (2004) Characteristic retinal atrophy with secondary inverse optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111:1935–1942PubMedCrossRef

41.

Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PEM (2006) Detecting vigabatrin toxicity by imaging the retinal nerve fiber layer. Invest ophthalmol vis sci 47:917–924PubMedCrossRef

42.

Rebolleda G, Garcia Pérez JL, Munoz Negrete FJ (2005) Vigabatrin toxicity in children (letter). Ophthalmology 112:1322–1323PubMedCrossRef

Title: Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy
Authors: Ulrika Kjellström
Monica Lövestam-Adrian
Sten Andréasson
Vesna Ponjavic
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Documenta Ophthalmologica / Issue 2/2008
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-007-9108-3

At a glance: The STEP trials

Springer Medicine

Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

VEP maturation and visual acuity in infants and preschool children

A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis

A new method of extrapolating the sweep pattern visual evoked potential acuity

Electrophysiological monitoring in a patient with an optic nerve glioma

A comparison of signal detection techniques in the multifocal electroretinogram

Electroretinogram changes after scleral buckling surgery of retinal detachment